965 related articles for article (PubMed ID: 28065194)
1. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
[TBL] [Abstract][Full Text] [Related]
2. Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.
Hong SH; Shepherd MD; Scoones D; Wan TT
J Manag Care Pharm; 2005; 11(9):746-54. PubMed ID: 16300418
[TBL] [Abstract][Full Text] [Related]
3. The effect of generic competition on the price of brand-name drugs.
Lexchin J
Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
[TBL] [Abstract][Full Text] [Related]
4. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
Dickson SR; Kent T
JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
[TBL] [Abstract][Full Text] [Related]
5. AMCP Guide to Pharmaceutical Payment Methods, 2009 Update (Version 2.0).
Academy of Managed Care Pharmacy
J Manag Care Pharm; 2009 Aug; 15(6 Suppl A):S3-57, quiz S58-61. PubMed ID: 19678720
[TBL] [Abstract][Full Text] [Related]
6. Association Between Market Competition and Prices of Generic Topical Dermatology Drugs.
Li DG; Joyce C; Mostaghimi A
JAMA Dermatol; 2018 Dec; 154(12):1441-1446. PubMed ID: 30383117
[TBL] [Abstract][Full Text] [Related]
7. The Contribution Of New Product Entry Versus Existing Product Inflation In The Rising Costs Of Drugs.
Hernandez I; Good CB; Cutler DM; Gellad WF; Parekh N; Shrank WH
Health Aff (Millwood); 2019 Jan; 38(1):76-83. PubMed ID: 30615532
[TBL] [Abstract][Full Text] [Related]
8. Impact of European pharmaceutical price regulation on generic price competition: a review.
Puig-Junoy J
Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
[TBL] [Abstract][Full Text] [Related]
9. The impact of alternative pricing methods for drugs in California Workers' Compensation System: Fee-schedule pricing.
Wilson L; Turkistani FA; Huang W; Tran DM; Lin TK
PLoS One; 2018; 13(5):e0197449. PubMed ID: 29799850
[TBL] [Abstract][Full Text] [Related]
10. What do pharmaceuticals really cost in the long run?
Lakdawalla D; MacEwan JP; Dubois R; Westrich K; Berdud M; Towse A
Am J Manag Care; 2017 Aug; 23(8):488-493. PubMed ID: 29087143
[TBL] [Abstract][Full Text] [Related]
11. Pharmaceutical pricing benchmarks: governmental versus private sector.
Turkistani F; Sawad AB
J Comp Eff Res; 2020 Oct; 9(15):1091-1100. PubMed ID: 33052057
[No Abstract] [Full Text] [Related]
12. Reference pricing with endogenous generic entry.
Brekke KR; Canta C; Straume OR
J Health Econ; 2016 Dec; 50():312-329. PubMed ID: 27350294
[TBL] [Abstract][Full Text] [Related]
13. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Kesselheim AS; Avorn J; Sarpatwari A
JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
[TBL] [Abstract][Full Text] [Related]
14. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.
Levy MS
Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582
[TBL] [Abstract][Full Text] [Related]
15. Long-term Medicaid excess payments from alleged price manipulation of generic lorazepam.
Bian B; Gorevski E; Kelton CM; Guo JJ; Martin Boone JE
J Manag Care Pharm; 2012 Sep; 18(7):506-15. PubMed ID: 22971204
[TBL] [Abstract][Full Text] [Related]
16. Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement.
Danzon PM; Mulcahy AW; Towse AK
Health Econ; 2015 Feb; 24(2):238-52. PubMed ID: 24293058
[TBL] [Abstract][Full Text] [Related]
17. Association of authorized generic marketing with prescription drug spending on antidepressants from 2000 to 2011.
Cheng N; Banerjee T; Qian J; Hansen RA
J Am Pharm Assoc (2003); 2017; 57(3):341-348. PubMed ID: 28400255
[TBL] [Abstract][Full Text] [Related]
18. Firm- and drug-specific patterns of generic drug payments by US medicaid programs: 1991-2008.
Kelton CM; Chang LV; Guo JJ; Yu Y; Berry EA; Bian B; Heaton PC
Appl Health Econ Health Policy; 2014 Apr; 12(2):165-77. PubMed ID: 24550087
[TBL] [Abstract][Full Text] [Related]
19. Increased topical generic prices by manufacturers.
Bhatt MD; Bhatt BD; Dorrian JT; McLellan BN
J Am Acad Dermatol; 2019 May; 80(5):1353-1357. PubMed ID: 29544742
[TBL] [Abstract][Full Text] [Related]
20. Do higher-priced generic medicines enjoy a competitive advantage under reference pricing?
Puig-Junoy J
Appl Health Econ Health Policy; 2012 Nov; 10(6):441-51. PubMed ID: 22900924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
